Ocular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 3,296 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey Heier sold 3,296 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $10.78, for a total value of $35,530.88. Following the transaction, the insider directly owned 318,326 shares in the company, valued at approximately $3,431,554.28. This represents a 1.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Performance

Shares of OCUL stock opened at $10.77 on Thursday. The stock’s 50-day moving average price is $9.63 and its 200 day moving average price is $9.15. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.37 billion, a PE ratio of -7.58 and a beta of 0.93. Ocular Therapeutix, Inc. has a 52-week low of $6.23 and a 52-week high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.The company had revenue of $13.47 million during the quarter, compared to analysts’ expectations of $13.20 million. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the firm earned ($0.39) EPS. As a group, equities research analysts forecast that Ocular Therapeutix, Inc. will post -1.47 EPS for the current year.

Institutional Trading of Ocular Therapeutix

Large investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its stake in shares of Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,242 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Ocular Therapeutix in the 4th quarter valued at about $31,000. Hilton Head Capital Partners LLC increased its holdings in Ocular Therapeutix by 30.4% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix during the 4th quarter valued at about $61,000. Finally, Caitong International Asset Management Co. Ltd raised its position in Ocular Therapeutix by 420.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 6,412 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 5,179 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

OCUL has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Robert W. Baird boosted their target price on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Chardan Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus target price of $25.75.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.